New study tracks arthritis drug safety in kids
NCT ID NCT05754710
First seen Nov 19, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This study watches how safe and effective Xeljanz is for children aged 2 to 17 with active juvenile arthritis or psoriatic arthritis in everyday Korean clinics. About 10 kids will be followed for up to 44 weeks. The goal is to check for side effects and see how well the medicine works in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.